SMA May Be Linked to Cognitive Impairment in Chinese Patients
A cross-sectional study suggests that spinal muscular atrophy (SMA) can contribute to cognitive impairment.
Source: ajmc.com
📰 Revised Upper Limb Module News
Revised Upper Limb Module News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Revised Upper Limb Module. Real-time updates on events, politics, business and more.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript
Rushmie Nofsinger: Good morning. Im Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations at Scholar Rock.
Source: insidermonkey.com
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript November 7, 2023 Rushmie Nofsinger: Good morning. I’m Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations at Scholar Rock. Welcome, and thank you for joining us today for our Q3 2023 Business Update Call. This call is audio-only. You can access the slides […]
Mo Qatanani Ted Myles Green Energy Stocks To Head Of Research Revised Upper Limb Module Ken Fisher Super Stocks
Source: yahoo.com
Risdiplam May Be Safe and Effective in SMA Care
Risdiplam appears to be an effective therapeutic option for patients with spinal muscular atrophy, leading to improved motor function, a study found.
United States Philadelphia Infant Test Neuromuscular Disorders Hammersmith Infant Neurological Exam Motor Function Measure Revised Upper Limb Module
Source: neurologyadvisor.com
NHI to cover NT$49 million gene therapy drug for muscle atrophy
Taipei, June 24 (CNA) A one-time-only drug to treat spinal muscular atrophy (SMA) that will cost NT$49 million (US$1.58 million) will soon be covered for infants six months old and under by Taiwan's universal health insurance system.
T Ai Pei United States Shen Pei Yao National Health Insurance Administration Deputy Director General Tsai Shu Ling Revised Upper Limb Module
Source: focustaiwan.tw
SMA in Adults: Interim Data Back Nusinersen Efficacy
New trial focuses on drug's performance in spinal muscular atrophy beyond childhood
University Of Rochester New York United States John Gever Health Index National Institute Of Neurological Disorders
Source: medpagetoday.com
New Four-Year Data for Genentech's Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA) Seite 1
20.03.2023 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data for Evrysdi (risdiplam) in a broad range of people aged 2-25 years with spinal muscular atrophy (SMA) from the pivotal SUNFISH study. Data ... Seite 1
Laurent Servais Levi Garraway Muscular Dystrophy Association Roche Group Global Product Development Oxford Neuromuscular Centre
Source: wallstreet-online.de
F. Hoffmann-La Roche Ltd: New four year data for Roche's Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
Data from pivotal SUNFISH study showed increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to decrease
Source: finanznachrichten.de
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play
Source: finanznachrichten.de
Nusinersen May Stabilize Disease Status in SMA Types 2 and 3
Treatment with nusinersen may decrease disease progression in pediatric patients who are nonambulatory with spinal muscular atrophy types 2 and 3.
Source: neurologyadvisor.com